Article
Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations.
The Journal of experimental medicine - 15 Feb 2010
Gross Stefan, Cairns Rob A, Minden Mark D, Driggers Edward M, Bittinger Mark A, Jang Hyun Gyung, Sasaki Masato, Jin Shengfang, Schenkein David P, Su Shinsan M, Dang Lenny, Fantin Valeria R, Mak Tak W
Abstract excerpt
Mutations in isocitrate dehydrogenase 1 and 2 (IDH1/2), are present in most gliomas and secondary glioblastomas, but are rare in other neoplasms. IDH1/2 mutations are heterozygous, and affect a single arginine residue. Recently, IDH1 mutations were identified in 8% of acute myelogenous leukemia (AML) patients. A glioma study revealed that IDH1 mutations cause a gain-of-function, resulting in the production and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.